Tumor-associated antigen-specific T cell (null)

Tumor-associated antigen-specific T cells are a subset of T lymphocytes—principally CD8^+^ cytotoxic and CD4^+^ helper T cells—that selectively recognize peptide antigens (tumor-associated antigens) presented by cancer cells via major histocompatibility complex (MHC) molecules[1][2][3][4][5]. These cells arise naturally or can be engineered with specific TCRs and are characterized by tumor enrichment, clonal expansion, and specificity for mutant or aberrantly expressed tumor proteins. They mediate anti-tumor immunity by direct killing of tumor cells and secretion of cytokines. Their functional status (e.g., exhaustion, activation) and abundance within tumors serve as important predictive biomarkers for immunotherapy response. They are central to adoptive cell therapies—including TCR-engineered T cell and CAR T cell approaches—but pose therapeutic challenges due to antigen heterogeneity, immune escape, and potential off-target toxicity[1][2][3][4][5][6].

Other names

TAA-specific T cellTumor antigen-specific T cellTumor-reactive T cell

Recognition of tumor-associated antigens presented by HLA molecules on cancer cells, leading to cytolytic attack Activation and expansion by antigen stimulation (native or engineered TCR or CAR) Modulation by immune checkpoint blockade to restore or enhance T cell responses[1][4][5]